The TGTX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the TGTX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The TGTX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View TGTX Detailed Price Forecast - CNN Money||View TGTX Detailed Summary - Google Finance|
|View TGTX Detailed Summary - Yahoo! Finance||View TGTX Stock Research & Analysis - Zacks.com|
|View TGTX Trends & Analysis - Trade-Ideas||View TGTX Major Holders - Barrons|
|View TGTX Call Transcripts - NASDAQ||View TGTX Breaking News & Analysis - Seeking Alpha|
|View TGTX Annual Report - CompanySpotlight.com||View TGTX OTC Short Report - OTCShortReport.com|
|View TGTX Fundamentals - TradeKing||View TGTX SEC Filings - Bar Chart|
|View Historical Prices for TGTX - The WSJ||View Performance/Total Return for TGTX - Morningstar|
|View the Analyst Estimates for TGTX - MarketWatch||View the Earnings History for TGTX - CNBC|
|View the TGTX Earnings - StockMarketWatch||View TGTX Buy or Sell Recommendations - MacroAxis|
|View the TGTX Bullish Patterns - American Bulls||View TGTX Short Pain Metrics - ShortPainBot.com|
|View TGTX Stock Mentions - StockTwits||View TGTX Stock Mentions - PennyStockTweets|
|View TGTX Stock Mentions - Twitter||View TGTX Investment Forum News - Investor Hub|
|View TGTX Stock Mentions - Yahoo! Message Board||View TGTX Stock Mentions - Seeking Alpha|
|View Insider Transactions for TGTX - SECform4.com||View Insider Transactions for TGTX - Insider Cow|
|View TGTX Major Holdings Summary - CNBC||View Insider Disclosure for TGTX - OTC Markets|
|View Insider Transactions for TGTX - Yahoo! Finance||View Institutional Holdings for TGTX - NASDAQ|
|View TGTX Stock Insight & Charts - FinViz.com||View TGTX Investment Charts - StockCharts.com|
|View TGTX Stock Overview & Charts - BarChart||View TGTX User Generated Charts - Trading View|
TG Therapeutics, Inc. (TGTX) and Novimmune SA, today announced that the companies have entered into an exclusive global agreement to collaborate on the development and commercialization of Novimmune’s novel first-in-class anti-CD47/anti-CD19 bispecific antibody known as TG-1801 (previously NI-1701). TG Therapeutics will make up-front and milestones payments based on early clinical development, and will be responsible for the costs of clinical development of the products through the end of Phase II, after which TG Therapeutics and Novimmune will be jointly responsible for all development and commercialization costs of the product.
TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab in Patients with Multiple Sclerosis at the 4th Congress of the European Academy of Neurology
Posted on Monday June 18, 2018
TG Therapeutics, Inc. (TGTX), today announced updated results from the Phase 2 multicenter trial of ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS). The data is being presented today at the 4th Congress of the European Academy of Neurology in Lisbon, Portugal, via an oral session titled “MS and related Disorders 2”, at 17:00 CET. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, stated, “We are extremely pleased to see that the preliminary Week 48 data presented today from this Phase 2 trial supports the Week 24 data presented earlier this year at the AAN meeting.
TG Therapeutics, Inc. Presents Phase 2 Data Evaluating Umbralisib in CLL Patients Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy at the 23rd Congress of the European Hematology Association (EHA)
Posted on Monday June 18, 2018
TG Therapeutics, Inc. (TGTX), today announced an oral presentation of clinical data from its ongoing Phase 2 study evaluating umbralisib (TGR-1202), the Company’s PI3K delta inhibitor, in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) who are intolerant to prior BTK or PI3K delta inhibitor therapy. Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, stated, “We are pleased to present data evaluating umbralisib in patients intolerant to currently approved BTK or PI3K therapies during the EHA annual congress.
TG Therapeutics, Inc. (TGTX), today announced the presentation of an integrated analysis of long term safety data of umbralisib (TGR-1202), the Company’s PI3K delta inhibitor, either dosed as a single agent and in combination, in patients with relapsed or refractory lymphoid malignancies, as well as the first preclinical data presentation of TG-1701, the Company’s orally available and covalently-bound BTK inhibitor. Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, stated, “We are extremely pleased to present updated data from our integrated safety analyses of umbralisib.